Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

(Reuters) -Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics, which makes treatments for ...

Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for ...

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in postpartum depression ...

Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing.